Wedbush Reiterates an 'Outperform' on HeartWare International (HTWR)

November 3, 2009 9:16 AM EST

Wedbush reiterates an Outperform rating on HeartWare International (Nasdaq: HTWR). Price target $40.

Wedbush analyst says, "During the earnings call, we will be focused on: (1) European commercialization of the HVAD; (2) progress in the ongoing pivotal US trial in BTT; (3) plans to initiate a pivotal US trial in DT; and (4) progress in the preclinical development of HTWR's next generation devices...Near-term milestones are focused on HVAD trials and European Commercialization...In Q4:2009, we expect HTWR to have initiated implantations at 28 / 40 of the US BTT trial centers, with at least 100 US implants completed. In Q1:2010, we also expect HTWR to select its choice of next-generation MVAD. Finally in H1:2010, we expect HTWR to complete enrollment of the US BTT trial and also commence the US DT clinical trial."

To see more analyst ratings on HTWR Click Here.

HeartWare International, Inc., a medical device company, focuses on developing and commercializing a family of blood pumps that are surgically implanted to help augment blood circulation in patients suffering from chronic and end-stage heart failure.

Related Categories

Analyst Comments

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?